Key facts
- It has raised $4.2M; the latest was Later Stage VC ($4.2M) in Aug 2025.
- Notable investors include Green Pine Capital Partners, Daoyuan Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Aoda Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Aoda Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aoda Biotechnology
Manufacturer of innovative peptide pharmaceuticals aims to advance targeted therapy and improve patient outcomes. The company's offerings feature long-acting and targeted peptide drug R&D, helping customers benefit from highly specific, effective, and low-side-effect treatments, enabling progress in antiviral, anticancer, and antibacterial therapies.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2017
- Employees
- 20
- Website
- aodashengwu.com/
- Ownership
- Privately Held (backing)
Aoda Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aoda Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aoda Biotechnology in its N-PORT filings yet. We sweep new filings monthly.